The FDA leadership's 2025 framework piece arguing that new COVID-19 vaccine approvals should be limited to adults 65 and older and people at high risk unless randomized trial data support broader use.
The FDA leadership's 2025 framework piece arguing that new COVID-19 vaccine approvals should be limited to adults 65 and older and people at high risk unless randomized trial data support broader use. citation verified as NEJM Sounding Board, May 20, 2025 (NEJMsb2506929). Excerpt not located; do not quote beyond citation.